Research from Hardman & Co, Hardman & Co

Hardman & Co

Research from Hardman & Co

Investment research on quoted companies and funds

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise. Our clients are public and private businesses as well as fund managers, ranging from start-ups to £1 billion+ market capitalisations. Hardman & Co offers corporate research & consultancy, serving the needs of both public and private companies. We produce gold-standard research with a global reach for trading and investment companies, as well as providing market commentary and analysis. In addition, we carry out a number of bespoke investment-related assignments, including due diligence on bond listings, assessments of private company valuations and other corporate advisory services. We engage with the market through traditional and digital media, offering illuminating video content on corporate management strategy, results communication, interviews and in-house sector discussion.

Thematic (Sector/Industry)

<ul>
<li>The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.</li>
<li>Its main function is to highlight the attractions of life sciences investments over the long term.</li>
<li>For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.</li>
</ul>


The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.
Its main function is to highlight the attractions of life sciences investments over the long term.
For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.


Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The technology-driven modular housing Company provided an operational market update outlining its geographic expansion strategy and technology roll-out.</li>
<li>The Company has completed the computerisation and integration of the entire modular housing production process, creating fully automated, high-precision housing manufacturing platforms.</li>
<li>At the heart of the system is the Company's proprietary Vertical Panel Casting Machine combined with Glass Fibre Reinforced Gypsum wall technology, a blend of advanced materials science, precision automation, and architectural flexibility. </li>
</ul>


The technology-driven modular housing Company provided an operational market update outlining its geographic expansion strategy and technology roll-out.
The Company has completed the computerisation and integration of the entire modular housing production process, creating fully automated, high-precision housing manufacturing platforms.
At the heart of the system is the Company's proprietary Vertical Panel Casting Machine combined with Glass Fibre Reinforced Gypsum wall technology, a blend of advanced materials science, precision automation, and architectural flexibility. 


iFOREX Financial Trading / Equity Bottom-Up

<ul>
<li>Updated 10th June: iFOREX Financial Trading, the fintech business with a proprietary online and mobile trading platform for multi-asset contracts for difference, announced that its proposed IPO onto the Main Market, which was expected to occur in late June, will be briefly delayed.</li>
<li>A routine thematic compliance inspection commenced earlier this year in the BVI, which was disclosed in the Company's Registration Document, requires additional time to enable finalisation ahead of the IPO.</li>
<li>The inspection process is close to completion and the Company anticipates only a short delay to the IPO timetable. </li>
</ul>


Updated 10th June: iFOREX Financial Trading, the fintech business with a proprietary online and mobile trading platform for multi-asset contracts for difference, announced that its proposed IPO onto the Main Market, which was expected to occur in late June, will be briefly delayed.
A routine thematic compliance inspection commenced earlier this year in the BVI, which was disclosed in the Company's Registration Document, requires additional time to enable finalisation ahead of the IPO.
The inspection process is close to completion and the Company anticipates only a short delay to the IPO timetable. 


<ul>
<li>On Friday 6 June, File Forge Technology PLC (to be renamed Amirose London Holdings PLC), announced the completion of its acquisition of Amirose London Ltd and the Admission to trading on the Access Segment of the Aquis Stock Exchange.</li>
<li>Amirose provides contract manufacturing services in the personal care sector for global and boutique premium brands.</li>
<li>Turnover for the year ended 30 March 2024 was £12.7m and profits of £38.8k. </li>
</ul>


On Friday 6 June, File Forge Technology PLC (to be renamed Amirose London Holdings PLC), announced the completion of its acquisition of Amirose London Ltd and the Admission to trading on the Access Segment of the Aquis Stock Exchange.
Amirose provides contract manufacturing services in the personal care sector for global and boutique premium brands.
Turnover for the year ended 30 March 2024 was £12.7m and profits of £38.8k. 


Oxford Nanopore Technologies / Equity Bottom-Up

<ul><li>Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets.</li><li>Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from profitability.</li><li>Despite this, some companies can still make extremely attractive returns for investors.</li></ul>

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets.Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from profitability.Despite this, some companies can still make extremely attractive returns for investors.

United Kingdom

Tissue Regenix Group is an international medical technology company specializing in regenerative products using its dCELL® and BioRinse™ platform technologies. These technologies address soft tissue and bone allograft needs through products like DermaPure® for soft tissue repair and ConCelltrate® for bone regeneration, primarily serving the BioSurgery, Orthopaedics, and Dental markets. The company was founded in 2006 in Leeds, UK, and has operations in the UK and US.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Tissue Regenix (LSW GR)

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments...

Hardman & Co

Hybridan Small Cap Feast: 16/10/2025

The technology-driven modular housing Company provided an operational market update outlining its geographic expansion strategy and technology roll...

Hybridan

Hybridan Small Cap Feast: 25/06/2025

A routine thematic compliance inspection commenced earlier this year in the BVI, which was disclosed in the Company's Registration Document

Hybridan

Hybridan Small Cap Feast: 09/06/2025

Turnover for the year ended 30 March 2024 was £12.7m and profits of £38.8k. Draft unaudited accounts for the year ended 30 March 2025 showed a...

Hybridan

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to...

Hardman & Co

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)